Evotec And The Jain Foundation Expand Collaboration
News Sep 15, 2014
Evotec AG and the Jain Foundation Inc. have further extended and expanded the collaboration first signed in 2012 and extended last year.
This next phase of collaboration includes the screening of compound libraries in multiple assay formats to further support the Jain Foundation’s goals of understanding and curing dysferlinopathies, a group of inherited skeletal muscular dystrophy diseases. This marks a major milestone in the efforts of the Jain Foundation to identify therapeutics which can counteract the phenotypes of dysferlin deficiency.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We are delighted to continue our relationship with the Jain Foundation and to be a part of this important step in dysferlin research. The progress to date and initiation of multiple screening programmes is a major accomplishment for both organisations and demonstrates Evotec‘s growing role in driving innovative and industrialised research in partnership with foundations such as the Jain Foundation working in rare diseases.“
Dr Plavi Mittal, President and CEO of Jain Foundation, added: ”We are pleased with the progress of our project with Evotec to date, and are excited to move forward to the screening phase of our drug development programme."
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018